FGFR4 ASO reduced hepatic FGFR4 expression, and lowered adiposity of DIO mice under caloric restriction.

<p>DIO mice were treated with saline, control (Cont) ASO or FGFR4 ASO #2 at 50 mg/kg/week for 8 weeks. Two weeks after the initiation of the treatment, Cont ASO-treated group (Cont ASO-CR), FGFR4 ASO-treated group (FGFR4 ASO-CR) and a group of saline-treated mice (Saline-CR) were subjected to caloric restriction by providing 90% of the amount of the food consumed daily by FGFR4 ASO group during the first 2 weeks of treatment; another group of saline-treated mice (Saline-AL) remained on free access to food. (A) Liver FGFR4 mRNA levels after 8 weeks of treatment. (B) BW changes during the treatment. (C) Total body fat content at different time points of the treatment. (D) Whole body O₂ consumption rate (VO₂). Data are expressed as mean ± SEM (n = 6–9/group). *<i>P</i><0.05; **<i>P</i><0.01; NS, not significant.